Harika-Germaneau Ghina, Wassouf Issa, Le Tutour Tom, Guillevin Remy, Doolub Damien, Rostami Reza, Delbreil Alexia, Langbour Nicolas, Jaafari Nematollah
Centre Hospitalier Henri Laborit, Unité de Recherche Clinique Pierre Deniker, Poitiers, France.
Centre de Recherches sur la Cognition et l'Apprentissage, Centre National de la Recherche Scientifique (CNRS 7295), Université de Poitiers, Poitiers, France.
Front Psychiatry. 2022 May 20;13:894473. doi: 10.3389/fpsyt.2022.894473. eCollection 2022.
Repetitive transcranial magnetic stimulation (rTMS) has proven to be an efficient treatment option for patients with treatment-resistant depression (TRD). However, the success rate of this method is still low, and the treatment outcome is unpredictable. The objective of this study was to explore clinical and structural neuroimaging factors as potential biomarkers of the efficacy of high-frequency (HF) rTMS (20 Hz) over the left dorso-lateral pre-frontal cortex (DLPFC).
We analyzed the records of 131 patients with mood disorders who were treated with rTMS and were assessed at baseline at the end of the stimulation and at 1 month after the end of the treatment. The response is defined as a 50% decrease in the MADRS score between the first and the last assessment. Each of these patients underwent a T1 MRI scan of the brain, which was subsequently segmented with FreeSurfer. Whole-brain analyses [Query, Design, Estimate, Contrast (QDEC)] were conducted and corrected for multiple comparisons. Additionally, the responder status was also analyzed using binomial multivariate regression models. The explored variables were clinical and anatomical features of the rTMS target obtained from T1 MRI: target-scalp distance, DLPFC gray matter thickness, and various cortical measures of interest previously studied.
The results of a binomial multivariate regression model indicated that depression type ( = 0.025), gender ( = 0.010), and the severity of depression ( = 0.027) were found to be associated with response to rTMS. Additionally, the resistance stage showed a significant trend ( = 0.055). Whole-brain analyses on volume revealed that the average volume of the left part of the superior frontal and the caudal middle frontal regions is associated with the response status. Other MRI-based measures are not significantly associated with response to rTMS in our population.
In this study, we investigated the clinical and neuroimaging biomarkers associated with responsiveness to high-frequency rTMS over the left DLPFC in a large sample of patients with TRD. Women, patients with bipolar depressive disorder (BDD), and patients who are less resistant to HF rTMS respond better. Responders present a lower volume of the left part of the superior frontal gyrus and the caudal middle frontal gyrus. These findings support further investigation into the use of clinical variables and structural MRI as possible biomarkers of rTMS treatment response.
重复经颅磁刺激(rTMS)已被证明是治疗难治性抑郁症(TRD)患者的一种有效治疗选择。然而,这种方法的成功率仍然较低,且治疗结果难以预测。本研究的目的是探索临床和结构神经影像学因素,作为高频(HF)rTMS(20Hz)作用于左侧背外侧前额叶皮质(DLPFC)疗效的潜在生物标志物。
我们分析了131例接受rTMS治疗的情绪障碍患者的记录,并在刺激结束时、治疗结束后1个月进行基线评估。反应定义为首次评估和末次评估之间蒙哥马利-艾斯伯格抑郁量表(MADRS)评分降低50%。这些患者均接受了脑部T1 MRI扫描,随后用FreeSurfer进行分割。进行全脑分析[查询、设计、估计、对比(QDEC)]并对多重比较进行校正。此外,还使用二项式多变量回归模型分析反应者状态。所探索的变量是从T1 MRI获得的rTMS靶点的临床和解剖特征:靶点-头皮距离、DLPFC灰质厚度以及先前研究的各种感兴趣的皮质测量指标。
二项式多变量回归模型的结果表明,抑郁类型(P = 0.025)、性别(P = 0.010)和抑郁严重程度(P = 0.027)与rTMS反应相关。此外,抵抗阶段显示出显著趋势(P = 0.055)。基于体积的全脑分析表明,额上回和额中回尾部左侧部分的平均体积与反应状态相关。在我们的研究人群中,其他基于MRI的测量指标与rTMS反应无显著相关性。
在本研究中,我们在一大群TRD患者中研究了与左侧DLPFC高频rTMS反应性相关的临床和神经影像学生物标志物。女性、双相抑郁障碍(BDD)患者以及对HF rTMS抵抗性较低的患者反应更好。反应者的额上回和额中回尾部左侧部分体积较小。这些发现支持进一步研究将临床变量和结构MRI作为rTMS治疗反应的可能生物标志物。